In order to develop effective therapies targeting CDK1 inhibition, clinical trials should measure the CDK1 tumour expression of PDAC patients before and during treatment in order to keep track of how CDK1 expression is affected by the therapy. This evidence concerns the gene CDK1 and neoplasm.